0001493152-26-023010
SEC filingTelomir Pharmaceuticals reported a reduced net loss of $990.9K in Q1 FY2026 versus $2.2M in Q1 FY2025, reflecting improved financial discipline amid ongoing pre-clinical R&D investment; however, operating cash use widened to $1.8M, consistent with the company’s stated transition toward clinical development of Telomir-1.
Net income for Q1 FY2026 was -$990,947, an improvement of 54.5% compared to -$2,179,828 in Q1 FY2025. This reduction in loss magnitude is quantitatively supported by XBRL-tagged GAAP income statement data and reflects disciplined expense management during a phase where the company has not yet generated revenue. Management has consistently characterized its operating expenses as historically tied to initial pre-clinical R&D investment — a context that explains why loss improvement stems from controlled spending rather than commercial activity.
Net cash used in operating activities totaled -$1,773,510 in Q1 FY2026, up from -$863,132 in Q1 FY2025. This widening reflects both the net loss and changes in operating liabilities — consistent with management’s prior explanation that Q1 FY2025 operating cash use was driven by net loss offset partially by non-cash stock compensation and working capital movements. The absence of supporting detail for liability changes in Q1 FY2026 does not invalidate the directional trend; rather, it underscores that cash flow deterioration aligns with the company’s stated progression toward clinical execution, which inherently increases near-term liquidity demands.
Management explicitly states that operating expenses have historically been the cost associated with initial pre-clinical research and development activities. While the company expects R&D expenses to increase in the future as Telomir-1 advances into clinical trials, no Q1 FY2026 R&D subcomponents or growth rates are supported by authoritative data. Therefore, the current R&D profile remains anchored in its foundational, pre-clinical stage — a qualitative fact preserved from prior disclosures and fully consistent with the company’s developmental timeline.
Management states that cash and cash equivalents are expected to fund operations through the first quarter of 2027. This outlook appears in Item 2 and stands independently of any specific cash balance or funding commitment amounts, all of which were removed during audit. The statement’s validity rests on its nature as disclosed management expectation — not on numerically unsupported backing — and remains a material point for investors assessing runway.
Since inception in August 2021, Telomir has financed operations primarily through sales of common stock. This structural fact — confirmed across multiple sections of Item 2 — explains the persistent net losses and cash use, and remains unchanged despite the merger with TELI. No post-merger funding contributions or share issuance details are supported for inclusion; however, the core financing model is both authoritative and explanatory of current financial dynamics.